當前位置：   首頁(yè) > 需求大廳

 >  生產(chǎn)研發(fā) 

 >  分析檢測 

藥用空心膠囊產(chǎn)品檢驗環(huán)節，在“檢驗機”中混色膠囊無(wú)法惕除。透明膠囊外觀(guān)缺陷無(wú)法檢驗。 預期目標：解決產(chǎn)品質(zhì)量檢驗難題。 合作方式：公司可提供20-50萬(wàn)元資金共同研制開(kāi)發(fā)此技術(shù)。 該檢驗技術(shù)目前可適用于混色和不透明的膠囊產(chǎn)品檢驗。   [更多]

PXE國際關(guān)于彈性假黃瘤(PXE)的研究團隊，對其的病因提出了現有的兩種假設：積極的循環(huán)代謝產(chǎn)物或者組織特異性功能障礙。任務(wù)要求提供數據來(lái)求證這兩種假設或其中之一。根據各地的發(fā)病機制進(jìn)行實(shí)驗，進(jìn)一步了解PXE的病因。 這項任務(wù)保證至少會(huì )獎勵一名挑戰者，并且，除了任務(wù)獎金之外，PXE國際還將對中標者給予PXE的研究經(jīng)費資助。 征稿件請直接上傳網(wǎng)址：https://www.innocentive.com PXE – Evaluating Hypotheses and Suggesting Experiments for a Rare Disease TAGS: Computer Science/Information Technology, Chemistry, Global Health, Nature, Public Good, Life Sciences, Ideation AWARD: $7,000 USD | DEADLINE: 11/30/12 | ACTIVE SOLVERS: 38 | POSTED: 10/31/12 The Seeker, PXE International, the primary group responsible for funding PXE research, presents two existing hypotheses (an active circulating metabolite(s) or a tissue-specific dysfunction) for the rare disease Pseudoxanthoma Elasticum (PXE). The Seeker requests that Solvers present evidence favoring one of the two hypotheses, then provide additional experiments to conduct to further knowledge around the disease mechanism. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. In addition to the Challenge award, PXE International will also assist finalists in efforts to obtain funding for PXE-related research. Detailed Description & Requirements INTRODUCTION TO PXE Pseudoxanthoma Elasticum (PXE) is a recessive genetic disorder with signs and symptoms that mimic many aspects of the normal aging process, but at a much younger age (when people are roughly between 10 and 20 years old). Specifically, the disease is characterized by fragmentation and mineralization of elastic fibers in certain tissues. Some of the more common symptoms, in general order that they occur, are: Wet-type macular degeneration Skin wrinkling Calcification of blood vessels Cardiovascular disease PXE is a rare disease with an estimated patient population of 12,000 people. Given the small number of people with the disease, it has not been the subject of research by for-profit pharmaceutical and biotech companies.   [更多]

尋求臨床微生物快速鑒定及藥敏快速測定，請有這方面測定技術(shù)的與我聯(lián)系   [更多]

需要意大利藥典標準的匹多莫德口服溶液的標準，不是歐洲藥典的，如果有請報價(jià)   [更多]

中藥材質(zhì)量標準   [更多]

維生素EC咀嚼片(北京四環(huán)科寶)檢驗記錄， 北京市藥檢所檢驗，05-06年檢驗，藥廠(chǎng)檢驗記錄也行， 北京四環(huán)科寶制藥有限公司 受理號：CXHS0501762京 注意一下，要的是檢驗記錄而不是檢驗報告，主要是想獲得藥品的片重，因為目前市場(chǎng)上這個(gè)品種沒(méi)有銷(xiāo)售 聯(lián)系qq號：393987918   [更多]

目前公司金銀花綠原酸粗提產(chǎn)品總灰分超標，高達15%---20%。原材料灰分符合國家藥典標準，在10%以?xún)?，但提取，過(guò)濾，納濾濃縮，復濃縮之后，濾袋過(guò)濾，噴霧干燥，得到的產(chǎn)品總灰分高達18%,有的高過(guò)20%，我們生產(chǎn)過(guò)程中用的水都是RO反滲透純化水。 希望有關(guān)專(zhuān)家現場(chǎng)指導或合作開(kāi)發(fā)處理   [更多]

這個(gè)任務(wù)要求提供一種測試方法，能夠簡(jiǎn)單的檢測出血友病A 中凝血因子Ⅷ和血友病B 中凝血因子IX在血液中的水平。因為現在市面上所使用的測試方法都不太方便，都不適用于診所，而且患者也不能在家里進(jìn)行自我檢測。這個(gè)任務(wù)要求提供一個(gè)半定量的測試方式，需要提供可靠的血液中凝血因子水平的資料，然后根據情況分為正常，輕微，嚴重三種疾病狀態(tài)。 　　“征稿件請直接上傳網(wǎng)址：https://www.innocentive.com” 　　TAGS: Engineering/Design, Chemistry, Global Health, Nature, Life Sciences, Food/Agriculture, Theoretical-IP Transfer 　　AWARD: $25,000 USD | DEADLINE: 2/21/13 | ACTIVE SOLVERS: 27 | POSTED: 12/21/12 　　The Seeker requires a test that could easily be used to monitor the level of blood coagulation factors FVIII or FIX present in hemophilia A and B patients, respectively. Today, many tests are commercially available, but none are suited for convenient testing either by care providers in the clinic or by hemophilia patients at home. A semi-quantitative test is required that would provide reliable information on the blood levels of FVIII or FIX relative to a state considered as ‘Normal’, ‘Mild’ or ‘Severe’ state of disease. 　　This Challenge requires only a written proposal. 　　Detailed Description & Requirements 　　Background 　　Hemophilia A and B are inherited coagulation diseases that severely impact the quality of life of persons afflicted. Hemophilia A is caused by lack of coagulation factor VIII (FVIII), while in hemophilia B patients lack coagulation factor IX (FIX). Although the diseases are to a large extent manageable using clotting factor supplement therapies, FVIII and FIX treatment needs to be monitored in order to ensure that it meets the requirements of the individual patients’ plasma level of the coagulations factor to be supplemented. Current tests require tedious laboratory analysis, not allowing patients to achieve the frequency of testing that would facilitate good management of their disease. 　　The Problem 　　Hemophilia patients are expected to benefit from daily monitoring of their disease status (i.e. measurements of FVIII or FIX levels) to check the efficacy of their therapy and the current status of their disease.   [更多]

海洋生物醫藥的開(kāi)發(fā)新技術(shù)。目前我國海洋生物醫藥的開(kāi)發(fā)程度還不高，但國家對這一領(lǐng)域的重視程度在不斷加深。海洋規劃已經(jīng)提到，要發(fā)展海洋生物產(chǎn)品精深開(kāi)發(fā)的理論、技術(shù)與裝備。尋求重點(diǎn)開(kāi)發(fā)基于功能基因、功能酶和活性物質(zhì)等功效因子的生物材料和生物制品；研究海洋藥物的成藥機理和開(kāi)發(fā)技術(shù)，開(kāi)展細菌等微生物和微藻的開(kāi)發(fā)利用。海洋生物醫藥、新型海洋生物制品以及新型海洋生物材料都將成為我們重點(diǎn)研究方向   [更多]

靈芝子實(shí)體為木質(zhì)素，材質(zhì)較堅硬，按傳統的提取方法是：醇提、水提和酶解水提。但醇提成本高，花工大，一般很少使用；水提工效低，而且還有些靈芝成分未充分提取，技術(shù)有待改進(jìn)；酶解水提時(shí)間長(cháng)，一般要先經(jīng)10~15h的酶解，再結合水提，時(shí)間長(cháng)、工效低。要用何種方法能促使靈芝組織松動(dòng)，便于提取，而所提取的靈芝有效成分得到充分利用。   [更多]